[go: up one dir, main page]

AR119822A1 - Triazolopirimidinas como inhibidores de a2a / a2b - Google Patents

Triazolopirimidinas como inhibidores de a2a / a2b

Info

Publication number
AR119822A1
AR119822A1 ARP200102383A ARP200102383A AR119822A1 AR 119822 A1 AR119822 A1 AR 119822A1 AR P200102383 A ARP200102383 A AR P200102383A AR P200102383 A ARP200102383 A AR P200102383A AR 119822 A1 AR119822 A1 AR 119822A1
Authority
AR
Argentina
Prior art keywords
pyrimidin
amino
triazolo
benzonitrile
methyl
Prior art date
Application number
ARP200102383A
Other languages
English (en)
Inventor
Heeoon Han
Le Zhao
Wenqing Yao
xiaozhao Wang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR119822A1 publication Critical patent/AR119822A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto que se selecciona de: 3-(5-amino-2-((5-(3-aminofenil)-1H-tetrazol-1-il)metil)-8-(pirimidin-4-il)-[1,2,4]triazol[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((5-(6-metilpiridin-2-il)-1H-tetrazol-1-il)metil)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((5-(6-metoxipiridin-2-il)-1H-tetrazol-1-il)metil)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-2-((5-(piridin-2-il)1H-tetrazol-1-il)metil)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(2-((5-(1H-pirazol-1-il)-1H-tetrazol-1-il)metil)-5-amino-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-2-((5-(tiazol-4-il)-1H-tetrazol-1-il)metil)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-2-((5-(pirimidin-2-il)-1H-tetrazol-1-il)metil)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-2-((5-(pirazin-2-il)-1H-tetrazol-1-il)metil)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridazin-3-il)-2-((5-(piridin-2-il)-1H-tetrazol-1-il)metil)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((5-(piridin-2-il)-1H-tetrazol-1-il)metil)-8-(piridin-4-il)[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(2-(dimetilamino)piridin-4-il)-2-((5-(piridin-2-il)-1H-tetrazol-1-il)metil)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(2-aminopiridin-4-il)-2-((5-(piridin-2-il)-1H-tetrazol-1-il)metil)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-(2-fluoro-6-(piridin-4-il)bencil)-8-(piridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(2-aminopiridin-4-il)-2-(2-(2-aminopiridin-4-il)-6-fluorobencil)-[1,2,4]triazolo[1,5-c]pirimidin-7il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-2-(((3-metilpiridin-2-il)metil)amino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-etil-6-oxo-1,6-dihidropiridin-3-il)-2-(((3-metilpiridin-2-il)metil)amino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridazin-3-il)-2-(((3-metilpiridin-2-il)metil)amino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-2-((3-metilpiridin-2-il)metoxi)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridazin-3-il)-2-((3-metilpiridin-2-il)metoxi)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((3-metilpiridin-2-il)metoxi)-8-(3-metilpiridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(2,6-dimetilpiridin-4-il)-2-((3-metilpiridin-2-il)metoxi)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-etil-6-oxo-1,6-dihidropiridin-3-il)-2-((3-metilpiridin-2-il)metoxi)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-2-(((3-metilpiridin-2-il)metil)amino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)-2-fluorobenzonitrilo; 3-(5-amino-8-(1-etil-6-oxo-1,6-dihidropiridin-3-il)-2-(((3-metilpiridin-2-il)metil)amino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)-2-fluorobenzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridazin-3-il)-2-(((3-metilpiridin-2-il)metil)amino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)-2-fluorobenzonitrilo; 3-(5-amino-8-(2-metoxi-6-metilpiridin-4-il)-2-(((3-metilpiridin-2-il)metil)amino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)-2-fluorobenzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridazin-3-il)-2-(piridin-2-ilmetil)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((3-fluoropiridin-2-il)metoxi)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((3-fluoropiridin-2-il)metoxi)-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((3-fluoropiridin-2-il)metoxi)-8-(1-metil-6-oxo-1,6-dihidropiridazin-3-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((3-fluoropiridin-2-il)metoxi)-8-(3-metilpiridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(2,6-dimetilpiridin-4-il)-2-((3-fluoropiridin-2-il)metoxi)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((3-fluoropiridin-2-il)metoxi)-8-(2-metoxi-6-metilpiridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-(piridin-2-ilamino)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-2-(piridin-2-ilamino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridazin-3-il)-2-(piridin-2-ilamino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(3-metilpiridin-4-il)-2-(piridin-2-ilamino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(2,6-dimetilpiridin-4-il)-2-(piridin-2-ilamino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(2-metoxi-6-metilpiridin-4-il)-2-(piridin-2-ilamino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((6-metilpiridin-2-il)amino)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((piridin-2-iloxi)metil)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 2-((5-amino-7-(3-cianofenil)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-2-il)metoxi)nicotinonitrilo; 2-((5-amino-7-(3-cianofenil)-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-[1,2,4]triazolo[1,5-c]pirimidin-2-il)metoxi)nicotinonitrilo; 2-((5-amino-7-(3-cianofenil)-8-(1-metil-6-oxo-1,6-dihidropiridazin-3-il)-[1,2,4]triazolo[1,5-c]pirimidin-2-il)metoxi)nicotinonitrilo; 2-((5-amino-7-(3-cianofenil)-8-(3-metilpiridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-2-il)metoxi)nicotinonitrilo; 2-((5-amino-7-(3-cianofenil)-8-(2,6-dimetilpiridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-2-il)metoxi)nicotinonitrilo; 2-((5-amino-7-(3-cianofenil)-8-(2-metoxi-6-metilpiridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-2-il)metoxi)nicotinonitrilo; 3-(5-amino-2-((1-(piridin-2-il)etil)amino)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((2-(piridin-2-il)propan-2-il)amino)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((5-(piridin-2-il)-2H-tetrazol-2-il)metil)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((5-(pirimidin-2-il)-1H-tetrazol-1-il)metil)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(pirimidin-4-il)-2-((5-(pirimidin-4-il)-1H-tetrazol-1-il)metil)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((5-(piridin-3-il)-1H-tetrazol-1-il)metil)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((5-(piridin-4-il)-1H-tetrazol-1-il)metil)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-2-((6-metilpiridin-2-il)metoxi)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridazin-3-il)-2-((6-metilpiridin-2-il)metoxi)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((6-metilpiridin-2-il)metoxi)-8-(3-metilpiridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(2,6-dimetilpiridin-4-il)-2-((6-metilpiridin-2-il)metoxi)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(2-metoxi-6-metilpiridin-4-il)-2-((6-metilpiridin-2-il)metoxi)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((3,6-dimetilpiridin-2-il)metoxi)-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((3,6-dimetilpiridin-2-il)metoxi)-8-(1-metil-6-oxo-1,6-dihidropiridazin-3-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((3,6-dimetilpiridin-2-il)metoxi)-8-(3-metilpiridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((3,6-dimetilpiridin-2-il)metoxi)-8-(2,6-dimetilpiridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-((3,6-dimetilpiridin-2-il)metoxi)-8-(2-metoxi-6-metilpiridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-(((6-metilpiridin-2-il)metil)amino)-8-(pirimidin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-2-(((6-metilpiridin-2-il)metil)amino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(1-metil-6-oxo-1,6-dihidropiridazin-3-il)-2-(((6-metilpiridin-2-il)metil)amino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-2-(((6-metilpiridin-2-il)metil)amino)-8-(3-metilpiridin-4-il)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; 3-(5-amino-8-(2,6-dimetilpiridin-4-il)-2-(((6-metilpiridin-2-il)metil)amino)-[1,2,4]triazolo[1,5-c]pirimidin-7il)benzonitrilo; y 3-(5-amino-8-(2-metoxi-6-metilpiridin-4-il)-2-(((6-metilpiridin-2-il)metil)amino)-[1,2,4]triazolo[1,5-c]pirimidin-7-il)benzonitrilo; o una sal farmacéuticamente aceptable de estos.
ARP200102383A 2019-08-26 2020-08-25 Triazolopirimidinas como inhibidores de a2a / a2b AR119822A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962891685P 2019-08-26 2019-08-26

Publications (1)

Publication Number Publication Date
AR119822A1 true AR119822A1 (es) 2022-01-12

Family

ID=72422275

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102383A AR119822A1 (es) 2019-08-26 2020-08-25 Triazolopirimidinas como inhibidores de a2a / a2b

Country Status (19)

Country Link
US (3) US20210061809A1 (es)
EP (1) EP4021907A1 (es)
JP (1) JP7631317B2 (es)
KR (1) KR20220066074A (es)
CN (1) CN114585625A (es)
AR (1) AR119822A1 (es)
AU (1) AU2020337350A1 (es)
BR (1) BR112022003408A2 (es)
CA (1) CA3150766A1 (es)
CL (1) CL2022000457A1 (es)
CO (1) CO2022003457A2 (es)
CR (1) CR20220124A (es)
EC (1) ECSP22022322A (es)
IL (1) IL290529A (es)
MX (1) MX2022002219A (es)
PE (1) PE20230372A1 (es)
PH (1) PH12022550470A1 (es)
TW (1) TW202115082A (es)
WO (1) WO2021041360A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021138467A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Anti-cd73 antibodies and uses thereof
MX2022007573A (es) 2020-01-03 2022-09-23 Incyte Corp Terapia de combinación de inhibidor de grupo de diferenciación 73 (cd73) e inhibidor del receptor de adenosina a2a/a2b.
CA3236342A1 (en) 2021-11-19 2023-05-25 Crossignal Therapeutics, Inc. Adenosine receptor antagonists
CA3256033A1 (en) 2022-04-13 2023-10-19 Arcus Biosciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2
KR20250026469A (ko) 2023-08-17 2025-02-25 김택민 오염된 공기를 맑고 깨끗한 공기가 되도록 가공하거나 또는 방사능 오염수 또는 각종 슬러지와 쓰레기 또는 음식물 쓰레기 또는 축분이나 인분을 액비로 가공하는 자연친화적인 친환경 공법에 적용되는 친환경 물질분자 가공 시스템
CN120022278A (zh) * 2023-11-22 2025-05-23 英诺湖医药(杭州)有限公司 用于治疗癌症的化合物
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ATE257156T1 (de) * 1997-03-24 2004-01-15 Kyowa Hakko Kogyo Kk (1,2,4)triazolo(1,5-c)pyrimidin-derivate
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
NZ522783A (en) 2000-06-28 2004-07-30 Smithkline Beecham P Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
MXPA04004137A (es) 2001-10-30 2005-01-25 Novartis Ag Derivados de estauroesporina como inhibidores de la actividad de cinasa de tirosina del receptor flt3.
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
DK3611174T3 (da) * 2017-04-07 2022-07-04 Medshine Discovery Inc [1,2,4]triazolo[1,5-c]pyrimidinderivat som a2a-receptorinhibitor
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
DK3766884T3 (da) * 2018-04-28 2022-03-28 Medshine Discovery Inc Krystalform og salttype af triazolopyrimidinforbindelse og fremstillingsfremgangsmåde dertil
MX2020012376A (es) * 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
AR116315A1 (es) * 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos
CN113015530A (zh) * 2018-11-20 2021-06-22 默沙东公司 取代的氨基三唑并嘧啶和氨基三唑并吡嗪腺苷受体拮抗剂、药物组合物及其用途
US12414952B2 (en) * 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use

Also Published As

Publication number Publication date
US20230124485A1 (en) 2023-04-20
US20250034153A1 (en) 2025-01-30
IL290529A (en) 2022-04-01
CR20220124A (es) 2022-06-15
EP4021907A1 (en) 2022-07-06
CL2022000457A1 (es) 2022-10-21
CO2022003457A2 (es) 2022-05-20
AU2020337350A1 (en) 2022-03-10
WO2021041360A1 (en) 2021-03-04
JP7631317B2 (ja) 2025-02-18
MX2022002219A (es) 2022-06-14
CA3150766A1 (en) 2021-03-04
TW202115082A (zh) 2021-04-16
JP2022545923A (ja) 2022-11-01
PE20230372A1 (es) 2023-03-06
US20210061809A1 (en) 2021-03-04
KR20220066074A (ko) 2022-05-23
CN114585625A (zh) 2022-06-03
BR112022003408A2 (pt) 2022-05-17
PH12022550470A1 (en) 2023-02-27
ECSP22022322A (es) 2022-05-31

Similar Documents

Publication Publication Date Title
AR119822A1 (es) Triazolopirimidinas como inhibidores de a2a / a2b
JP2023504147A (ja) ユビキチンプロテオソーム経路を介したｂｔｋの分解のための二官能性化合物
RU2018138050A (ru) Производные тиазолопиридина как агонисты gpr119
RU2012130436A (ru) Новое антитромботическое средство
RU2015114936A (ru) Ингибиторы серин/треонинкиназы
MX2021014235A (es) Formas en estado sólido.
RU2012136643A (ru) [5,6]- гетероциклическое соединение
RU2008110915A (ru) Новые диазаспироалканы и их применение для лечения заболеваний, опосредованных ccr8
RU2012113593A (ru) Ингибиторы jak
RU2017134901A (ru) Соединения 1-циано-пирролидинов в качестве ингибиторов USP30
JP2018537408A5 (es)
JP2019514878A5 (es)
CL2008002717A1 (es) 3-(1-clorofenil)-7-oxo-6-[4-(2-oxo-1(2h)piridinil)fenil]-4,5,6,7-tetrahidro-1h-pirazolo[3,4-c]piridin-3-carboxamida y 3-(1-hidroxi-1-metil-etil)-1-(a-metoxi-fenil)-6-[4-(2-oxo-2h-piridin-1-il)-fenil]-1,4,5,6-tetrahidro-pirazolo[3,4-c]piridin-7-ona; composicion farmaceutica; combinacion farmaceutica y uso en el tratamiento de un desorden tromboembolico
JP2019526550A5 (es)
NZ589781A (en) Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
JP2016522232A5 (es)
JP2013542204A5 (es)
AP1767A (en) 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones.
HRP20201337T1 (hr) Inhibitori lizin-specifične demetilaze-1
SA520412192B1 (ar) مشتقات 5-(2-(2، 5-داي فلورو فنيل)بيروليدين-1-يل) -3-(1h-بيرازول-1-يل) بيرازولو[1، 5-a] بيريميدين والمركبات ذات الصلة كمثبطات كيناز trk لعلاج السرطان
DK3357922T3 (da) 2-((5-(1-(3-(methylsulfonyl)propyl)piperidin-4-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8h)-on-derivater og relaterede forbindelser som cdk4-inhibitorer til behandling af tumorer
RU2015100942A (ru) Производное пиперидинилпиразолпиридина
SI3081566T1 (en) DERIVAT 5-HYDROXY-4- (TRIFLUOROMETHYL) PIRAZOLOPYRIDINE
WO2015164520A4 (en) Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c] pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c] pyridine compounds as glyt1 inhibitors
JPWO2021041360A5 (es)